SEC-sourced researchBeta

KYMR

Kymera Therapeutics, Inc.

US markets

Data passport

CIK: 0001815442
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Oct 1, 2026
SEC registry record: Operating company

Last updated: Oct 6, 2026, 12:05 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

KYMR · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	78,592,000.0000	Feb 26, 2026
December 2024	47,072,000.0000	Feb 26, 2026
December 2025	39,211,000.0000	Feb 26, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	39,211,000.0000	-311,351,000.0000	-232,891,000.0000	1,742,812,000.0000	163,148,000.0000	Feb 26, 2026
December 2024	47,072,000.0000	-223,858,000.0000	-194,501,000.0000	978,035,000.0000	142,416,000.0000	Feb 26, 2026
December 2023	78,592,000.0000	-146,962,000.0000	-102,826,000.0000	—	—	Feb 26, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$39.21M	December 2025	Feb 26, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$47.07M	December 2024	Feb 26, 2026	10-K
Net incomeNetIncomeLoss	-$311.35M	December 2025	Feb 26, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$232.89M	December 2025	Feb 26, 2026	10-K
Total assetsAssets	$1.74B	December 2025	Feb 26, 2026	10-K
Total liabilitiesLiabilities	$163.15M	December 2025	Feb 26, 2026	10-K

New filings

Explore methodology ↗